Price Chart

Profile

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.
URL https://www.iterumtx.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 15, 2024 (est.)
Last Earnings Release Nov. 14, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.
URL https://www.iterumtx.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 15, 2024 (est.)
Last Earnings Release Nov. 14, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A